6
6
6
6
1
1
4
4
16
16
19
19
13
13
16
16
21
21
1
1
2019
2010
Company (107)Hospital (2)University (2)
1 - 10 of 107
Sort by
Clinical Trial
Clinical Trial IDNCT03385486Start Date2018-11-01Completion Date2022-04-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors. The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity. The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.
Patent
Publication NumberUS 10087420StatusIssued PatentAvailabilityUnknownFiling Date2016-06-10Publication Date2018-10-02
Disclosed are methods for manipulating and expanding stem cell populations, including adult stem cells, the cells produced by such methods, and various protein constructs related thereto.
Patent
Publication NumberES 2681478 T3StatusOtherAvailabilityUnknownFiling Date2009-08-28Publication Date2018-09-13
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Clinical Trial
Clinical Trial IDNCT02860559Start Date2019-01-01Completion Date2023-03-01PhasePhase 1Study TypeInterventionalStatusNot yet recruiting
This is a study of stem cell transplantation with TBX-1400 in pediatric subjects with severe combined immunodeficiency (SCID). The donor cells are exposed to a protein that has been shown in the laboratory to improve the ability of the donor cells to make blood and immune cells after transplant. Exposure of the donor cells to this protein does not modify the genes in the cells in any way. This study has two goals. The first goal is to find out if transplant with TBX-1400 is safe. The second g…
Patent
Publication NumberDK 2966084 T3StatusOtherAvailabilityUnknownFiling Date2009-08-28Publication Date2018-08-06
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Patent
Publication NumberSG 10201803982T AStatusPatent ApplicationAvailabilityUnknownFiling Date2009-05-18Publication Date2018-07-30
ANTIBODIESAND PROCESSES FOR PREPARING THE SAME Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins. (NO SUITABLE FIGURE) -105-
Patent
Publication NumberAU 2013292330 B2StatusIssued PatentAvailabilityUnknownFiling Date2013-07-19Publication Date2018-07-12
The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC)…
Patent
Publication NumberUS 20180177827StatusPatent ApplicationAvailabilityUnknownFiling Date2017-07-06Publication Date2018-06-28
The present disclosure relates to the production of red blood cells from hematopoietic stem cells, by differentiating such cells in the presence of a protein that induces cell survival and proliferation.
Patent
Publication NumberEP 3339321 A1StatusPatent ApplicationAvailabilityUnknownFiling Date2009-08-28Publication Date2018-06-27
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
Patent
Publication NumberJP 2018095654 AStatusPatent ApplicationAvailabilityUnknownFiling Date2018-02-02Publication Date2018-06-21
PROBLEM TO BE SOLVED: To provide methods for enhancing reconstitution of hematopoietic compartment in subjects in need of hematopoietic stem cell transplantation.SOLUTION: Disclosed herein is a method comprising: (a) a step of obtaining a group of hematopoietic stem cells treated with a composition comprising a MYC composition or a Bcl-2 composition or both for less than about 13 days; and (b) administering to the subject a therapeutically effective amount of the group of treated hematopoieti…
We found 107 documents that match your Search
Research Grants: 8
Patents: 94
Clinical Trials: 2
SEC Filings: 3

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in